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Carbonaceous nanoparticles (CNP) are promising in a wide range of biomedical applications
including CNP-based vaccine adjuvants, drug carriers, and contrast agents.[1–3] As the most
potent antigen-presenting cells, dendritic cells (DCs), are actively engaged in shaping
immune responses whereby they are capable of inducing and maintaining both T cell-
mediated immunity and immune tolerance.[4] Thus, the use of nanomaterials for targeting
DC’s functions is an encouraging approach to novel therapies and vaccine development for
different immune-mediated diseases. However, studies on effects of nanomaterials on DC
functions are very limited. Recently, we have reported the modulation of DC functions by
single walled carbon nanotubes.[5] In the current study, we compared the regulation of key
DC functions by three CNPs with distinctive geometries and surface properties–planar and
negatively-charged graphene oxide (GO), non-charged “spherical” C60-fullerenes, and
negatively-charged “spherical” C60-TRIS fullerenes. We demonstrated the opposite
regulatory effects of the DC’s ability to prime antigen-specific T lymphocytes—suppression
or activation—by GO and C60-fullerenes, respectively. The inhibition of antigen
presentation in GO-treated DCs was not mediated by alterations of antigen engulfment or
MHCI/peptide - TCR interaction but was associated with down-regulation of intracellular
levels of subunit LMP7 of immunoproteasome responsible for antigens processing in DCs.
In silico modeling indicated that LMP7 preferentially binds to the basal plane of GO,
leading to a strong electrostatic association as compared to weaker hydrophobic modes of
binding of C60-fullerenes. The demonstrated strong dependence of functional and
phenotypic modulation of DCs by CNP with differing surface properties should be
considered when enhancement of the immunostimulatory or tolerogenic functions of DCs
are required for clinical utilization.
The CNP used in the present study were carefully characterized as described in the
Supporting Information (Figure S1, S2). The zeta potential was −13.6, −26.1, and −32.4 mV
for C60 fullerenes, C60-TRIS fullerenes, and GO, respectively. The average particle sizes
obtained by TEM were 45.2 ± 25.3 nm for C60 fullerenes and 45.6 ± 18.8 nm for C60-TRIS
(Figure S2). GO was characterized as previously described.[6]
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The key function of conventional DCs is the activation of antigen-specific T cells, which
relies on the efficient antigen capture, intracellular processing of protein antigens and
presentation of antigenic peptides within MHC/peptide complex on DC surface to antigen-
specific T lymphocytes recognizing antigenic peptides by T cell receptors (TCR).
Depending on the presence of additional co-stimulatory and cytokine-mediated stimuli
provided by DCs and the micro-environmental elements, T cell-mediated immunity,
unresponsiveness or tolerance may be induced and maintained. Furthermore, inefficient
DC/T cell interaction and antigen presentation may results in a weak immune response or T
cell suppression.[7] Therefore successful employment of nanomaterials to improve DC
loading with antigens or targeting other features of therapeutic DC vaccines should consider
the ability of CNP to affect the key function of DCs since both immunogenic or tolerogenic
properties of DCs may be unintentionally affected.
To determine how CNP may alter antigen-presenting activity of DCs in vitro, we first tested
whether nanomaterials could directly interact with DCs. Co-incubation of bone marrow-
derived DCs with GO, C60 and C60-TRIS fullerenes resulted in efficient incorporation of
CNP into the cells, as determined by visualization of aggregates of nanomaterials in DC
cytoplasm (Figure 1, inset). Next we examined the ability of different CNP to modify the
key function of DCs: presentation of antigens and activation of antigen-specific T cells.
To this end, we tested the capacity of control and CNP-treated DCs to present an antigen to
syngeneic T cells utilizing ovalbumin (OVA) as a model antigen. The CTL epitope and Th
epitope of this antigen have been well characterized and the model is well established in our
lab.[8] DCs were exposed to GO and fullerenes prior to OVA-loading and then mixed with
B3Z86/90.14 (B3Z) CD8+ T cells specific for the H-2Kb-restricted anti-mouse OVA257–
264 (SIINFEKL) peptide. Production of IL-2 by T cells reflected T cell activation upon
recognition of the OVA epitope 257–264 in the context of the H-2Kb molecules (MHC class
I). The results showed that pre-treatment of DCs with 6.25 µg/mL of C60 or C60-TRIS
fullerenes prior to antigen loading promoted the ability of DCs to activate OVA-specific T
cells. Higher dose of fullerenes (25 µg/mL), however, negatively affected stimulatory
capacity of DCs (Figure 2A). In contrast, pre-exposure of DCs to 6.25 and 25 µg/mL of GO
resulted in significantly impaired stimulatory potential of DCs (Figure 2A). These results
suggest that structural features of CNP may be responsible for their differential effects on
the ability of DCs to present antigens to T cells. They also demonstrate that, in spite of the
general belief that nanomaterials activate antigen presentation by DCs, CNP, e.g., GO, may
efficiently inhibit this key function of DCs. These important results open a new opportunity
to use DC vaccines not only for induction of immune responses, as required, e.g., in cancer,
but also to utilize DCs for the treatment of autoimmune disorders where inhibition of
antigen-specific immune responses is desirable.
It is important to note that exposure of DCs to CNP after loading with protein antigen did
not significantly affect the ability of DCs to stimulate antigen-specific B3Z cells (data not
shown). This suggests that tested CNP affected the processes associated with antigen uptake,
preparation or presentation and were ineffective after these steps were finalized. In fact,
presentation of antigenic peptides delivered from exogenous proteins, such as OVA, in the
context of MHC class I molecules (cross-presentation) requires endocytosis of the antigen
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and its subsequent processing by the multicatalytic proteases within the
immunoproteasomes.[9] The resulting short peptides (8–12 residues long) are translocated
into the endoplasmic reticulum and form complexes with MHC class I molecules. These
complexes are further transported to the cell surface to be presented to TCR on T cells.[9]
Our results revealed that antigen presenting potential of DCs was up- or down-regulated by
C60 fullerenes and GO, respectively, when cells were pre-treated with CNP prior to addition
of OVA. Thus, it is conceivable that CNP may interfere with either antigen uptake by DCs
(i.e., pinocytosis of soluble protein) or antigen processing by MHC class I antigen-
processing machinery (APM) components in DCs or presentation of antigenic peptides
within MHCI/peptide complex on DC surface to TCR on T cells. To better understand the
mechanisms of modulation of antigen-presenting function of DCs by CNP, we
experimentally tested each of these three pathways.
We evaluated whether CNP could alter the final step of antigen presentation, i.e., the
presentation of an OVA-related antigenic peptide, which does not require intracellular
proteasomal degradation processing and is readily presented by DCs after binding with
MHC class I molecules. Because DCs process OVA protein to a number of peptides,
including an octapeptide SIINFEKL, which is presented by H-2Kb (MHC class I)
complexes, we used SIINFEKL for loading into DCs pre-exposed to CNP. DCs were then
co-incubated with SIINFEKL-specific T cells as above to assess their ability to present the
antigen. The results revealed that GO did not suppress the antigen-presenting ability of DCs
loaded with OVA257–264 peptide (Figure 2B), in contrast to DCs loaded with the whole
OVA protein (as in Figure 2A). All tested CNP slightly, but significantly, elevated
presentation of SIINFEKL peptide by DCs, suggesting that the intracellular transport of the
peptide and its binding with MHC class I molecules in EPR or on the cell surface are not the
targets for CNP in DCs. Therefore this pathway, i.e., the final step of antigen presentation
during MHCI/peptide -TCR interaction, cannot explain the differential effects of GO and
fullerenes on DC ability to present antigens to T cells.
The next potentially targeted by CNP pathway in DCs is their endocytic activity. To test
whether exposure of DCs to GO could disrupt uptake of OVA in DCs, CNP-treated cells
were co-incubated with FITC-labeled OVA or Lucifer Yellow (LE) (as a control). Analysis
of incorporation of FITC-OVA and LY into DCs, which reflects the pinocytic activity of
cells, demonstrated that the amount of FITC-OVA and LY engulfed by DCs pre-treated with
CNP was similar to that seen in control DCs (p > 0.1, n = 3). For instance, uptake of FITC-
OVA, reflected by alteration of MFI was 7030 ± 786, 6723 ± 916, 6962 ± 889 and 6658 ±
779 MFI in DCs treated with medium, C60, C60-TRIS and GO, respectively. Similar results
were obtained for incorporation of LE in control and CNP-treated DCs. Therefore, GO
induced down-regulation of the antigen-presenting potential of DCs cannot be explained by
the GO effect on endocytic property of DCs.
Because GO did not alter antigen uptake and did not suppress presentation of an antigenic
peptide by DCs, the next potential mechanism of its inhibitory influence on DCs could be
the MHC class I antigen-processing machinery (APM). Processing of protein antigens in
DCs involves the cascade of protein fragmentation facilitated by immunoproteasomes. It has
been previously demonstrated that the activity of immunoproteasomes incorporating three
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proteolytic proteasome subunits (LMP2, LMP7 and MECL-1) is essential for the generation
of T cell epitopes.[10] Immunoproteasome-derived peptides are further transported to the
endoplasmic reticulum by the Transporters Associated with Antigen Processing (TAP1/2)
and loaded into MHC-I complexes. The loading of peptide into MHC I involves association
of MHC I heavy chain with calnexin and subsequent incorporation into peptide-loading
complex involving TAP, tapasin, calreticulin and ERp57. Binding of a peptide to MHC class
I molecule promotes its dissociation from the peptide-loading complex.[11, 12]
To determine whether CNPs interfere with MHC class I APM components in DCs, we
measured the expression of APM molecules in DCs after CNP treatment. The results
revealed that the exposure of DCs to GO resulted in significantly decreased levels of one of
the critical immunoproteosome subunits - LMP7. In contrast, incubation of DCs with C60
and C60-TRIS fullerenes did not result in significant changes in the APM components
(Table 1). These results identified a potential pathway and a protein targeted by GO in DCs
as mediators of the GO-induced inhibition of antigen-presenting potential of DCs. They also
raised a question about possible mechanisms of GO interactions with LMP7 that were not
realized upon treatment of DCs with C60 and C60-TRIS fullerenes.
To get a better insight into mechanisms of interactions between LMP7 and CNP, we
employed molecular modeling of 3D structures corresponding to C60 fullerenes and GO
sites for docking to LMP7 using Autodock Vina procedure.[13] The predicted binding mode
of C60 fullerene and GO on LMP7 is shown in Figure 3. All the predicted binding poses of
C60 fullerene on LMP7 were identical and localized in close proximity (with in 5 Å) to
residues T93, A94, G95, G119, C120, S168, S202, and Y241 (Figure 3a). In contrast to this,
the predicted binding site of LMP7 on GO was localized to a different region composed of
two overlapping binding sites (Figure 3b,c). The predicted binding sites were confined to
residues R102, N104, E108, R126, R129, Y139, R145, E216, P221, E222, Y225, R229,
K252, D254, G255, W256, V257, K258, V259, S261, D263, S265, D266, Y269 and K270.
While the predicted binding site in the case of C60 included hydrophobic and aromatic
residues, the GO binding site was mostly composed of charged residues. This indicates that
the GO interaction with LMP7 is due to a strong electrostatic contact between the
negatively-charged oxidized groups of GO and positively-charged residues on LMP7
molecules. Thus, the interaction between GO and LMP7 molecules was preferentially driven
by charged residues, while C60 fullerene occupied a different site on LMP7 with dominating
hydrophobic interactions (Figure 3). The electrostatic interaction of LMP7 with GO may
lead to a strong adsorption of LMP7 on GO, which cannot be easily disrupted, thus resulting
in the low levels of free intracellular LMP7 detected in GO-treated DCs. This strong GO/
LMP7 interaction likely prevented efficient processing of protein antigen by
immunoproteosomes in DCs, leading to a diminished antigen cross-presentation and T cell
response.
Our results indicated that GO, in contrast to C60 fullerenes, suppressed antigen processing in
DCs and thus down-regulated their ability to activate antigen-specific T lymphocytes.
However, several reports have showed that CNP are potent inducers of DC maturation, the
process commonly associated with increased ability of DCs to stimulate clonal expansion of
T cells. For instance, exposure of DCs to carbon black facilitated DC maturation in vitro.[14]
Tkach et al. Page 5






















Fullerene derivative [Gd@C(82)(OH)(22)](n) has been reported to induce phenotypic and
functional maturation of DCs, including increased production of IL-12.[15] Therefore, an
important question was whether GO shared similar properties with other CNP structures or
was unable to affect the maturation status of DCs: if GO does not up-regulate DC
maturation, it might probably block this process, which could also contribute in the GO
ability to suppress antigen presentation by DCs.
Consequently, we next evaluated expression of MHC and co-stimulatory molecules on DCs
exposed to C60, C60-TRIS and GO. Noteworthy, all CNP preparations were first examined
for the endotoxin content known as a potent inducer of DC maturation. We found that
endotoxin levels in CNPs were below the detection limit of chromogenic Limulus
amebocyte lysate (LAL) assay (0.01 EU/mL).[16] In these experiments, LPS served as a
positive control. As Table 2 shows, both GO and fullerenes induced increased expression of
co-stimulatory CD86 and CD80, as well as MHC molecules on DCs, suggesting that all
tested CNP share similar ability to cause DC maturation in vitro. In spite of this capacity, the
overall effect of GO on the ability of DC to activate antigen-specific T cells was negative
(Figure 2). However, the stimulatory potential of C60 fullerenes on DCs may, at least in part,
be explained by their ability to up-regulate expression of MHC and co-stimulatory
molecules.
While OVA-loaded DCs pre-exposed to GO were more phenotypically mature than control
OVA-loaded DCs, they failed to effectively prime OVA-specific MHC I-restricted antigen-
specific T cells. This indicates that GO-mediated regulation of APM represents the dominant
pathway of DC inhibition by GO. This is also supported by the fact that exposure of DCs to
CNP after OVA loading did not significantly affect the ability of DCs to stimulate antigen-
specific T cells. Overall, our data suggest that structural differences between CNP molecules
determine their ability to interfere with antigen processing in DCs and therefore control
DC’s ability to induce antigen-specific immune response. Our data also suggest that
evaluations of CNPs effects on phenotypic maturation of DCs cannot serve as a definitive
test for the immunogenic potential of DC vaccines. Indeed, in spite of commonly observed
induction of DC maturation, some CNP, e.g., graphene oxide, may cause the
immunosuppressive effect on the key functions of DCs, such as antigen presentation.
The results of our studies demonstrate that both C60 fullerenes and graphene capable of
modulating the antigen-specific T cell responses due to their ability to directly affect the
functional activity of DCs, the most potent antigen-presenting cells. Specifically, C60
fullerenes fostered the ability of DCs to stimulate T cells, in part by promoting phenotypic
maturation of DCs assessed as increased expression of MHC and co-stimulatory molecules
on DC surface. In contrast, GO disrupted the protein antigen processing in DCs by down-
regulating the levels of immunoproteasome LMP7 and, thus, diminishing the ability of DCs
to induce activation of antigen-specific T lymphocytes. This immunosuppressive effect of
GO dominated the ability of GO to potentiate maturation of DCs. Although our molecular
modeling experiments revealed strong electrostatic binding sites as defining GO/LPM7
interactions, further studies should fully explore the detailed mechanisms of GO-induced
effects on LMP7 expression in DCs and other cell. Moreover, our findings may provide new
opportunities for targeting components of antigen-processing machinery and thus controlling
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the development of autoimmune and other immune-mediated diseases. Our results also
emphasize the importance of careful and extensive assessments of immunomodulatory
effects of nanoparticles considered for diverse biomedical applications. Conversely, if
appropriately controlled, the immunoregulatory properties of CNPs may be exploited for
both immunostimulatory and immunosuppressive therapeutic gains.
Experimental Section
Experimental procedures are provided in the Supporting Information.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Scanning electron microscope (SEM)/transmission electron microscope (TEM) micrographs for C60 (A), C60-TRIS (B) and GO
(C) as seen in phosphate buffered saline (PBS) suspensions. Light microscopy images of cultured DCs engulfing CNP (A, B, C
inset). Notably, DCs were capable of effective CNP uptake.
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(A) IL-2 production by B3Z T cells stimulated by OVA-loaded DCs pre-exposed to CNP in vitro. GO exposure decreased the
ability of DCs to stimulate T cells, while fullerene exposure facilitated T cell responses. Data are shown as mean values ± SEM
(n = 3); *p < 0.05 vs. control, αp < 0.05 vs. exposure to 1.0 µg/mL, ωp < 0.05 vs. exposure to 6.25 µg/mL. (B) IL-2 production
by B3Z T cells stimulated by SIINFEKL (0.01 µM) peptide-loaded DCs pre-exposed to CNP (6.25 µg/mL) in vitro. Notably,
GO did not interfere with the cross-presentation of readily available antigenic peptide in DCs. Data are shown as mean values ±
SEM (n = 3); *p < 0.05 vs. control.
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Predicted interaction sites of C 60 and GO on LMP7. (A) The predicted binding site of C 60 on LMP7. The predicted interaction
(B) site 1 and (C) site 2 of GO on LMP7. LMP7 is represented as cartoon and is colored in blue-red from N-C terminus. The
residues that are predicted to be within close proximity (5Å) to either C60 or GO are represented as sticks. The structures of C60
and GO are represented as sticks and colored in dark grey, red and white to highlight the C, O and H atoms.
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Table 1
Expression on the major components of MCH class I antigen processing machinery by DCs after exposure to
CNP in vitro.a)
APM components Control DC C60 C60-Tris Graphene
Oxide
LMP2 183 ± 4 177 ± 3 179 ± 5 178 ± 10
LMP7 1348 ± 34 1380 ± 60 1514 ± 39 551 ± 16*
LMP10 (MECL-1) 467 ± 32 495 ± 16 503 ± 8 461 ± 19
ERp57 265 ± 3 289 ± 4 252 ± 14 261 ± 15
Calreticulin 785 ± 24 803 ± 15 826 ± 47 738 ± 76
TAP-1 1120 ± 54 1136 ± 39 1091 ± 25 1034 ± 51
Calnexin 1380 ± 23 1414 ± 27 1312 ± 27 1302 ± 13
a)
Data are shown as mean of fluorescence intensity (MFI) ± SEM (n = 3).
*
p < 0.05 vs. control non-treated DCs.
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